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Abstract: C-Met tyrosine kinase receptor plays an important role under normal and pathological
conditions. In tumor cells’ overexpression or incorrect activation of c-Met, this leads to stimulation
of proliferation, survival and increase of motile activity. This receptor is also described as a marker
of cancer initiating cells. The latest research shows that the c-Met receptor has an influence on the
development of resistance to targeted cancer treatment. High c-Met expression and activation in
renal cell carcinomas is associated with the progression of the disease and poor survival of patients.
C-Met receptor has become a therapeutic target in kidney cancer. However, the therapies used
so far using c-Met tyrosine kinase inhibitors demonstrate resistance to treatment. On the other
hand, the c-Met pathway may act as an alternative target pathway in tumors that are resistant
to other therapies. Combination treatment together with c-Met inhibitor reduces tumor growth,
vascularization and pro-metastatic behavior and results in suppressed mesenchymal phenotype and
vascular endothelial growth factor (VEGF) secretion. Recently, it has been shown that the acquirement
of mesenchymal phenotype or lack of cell differentiation might be related to the presence of the c-Met
receptor and is consequently responsible for therapy resistance. This review presents the results from
recent studies identifying c-Met as an important factor in renal carcinomas being responsible for
tumor growth, progression and metastasis, indicating the role of c-Met in resistance to antitumor
therapy and demonstrating the pivotal role of c-Met in supporting mesenchymal cell phenotype.
Keywords: C-Met receptor; therapy resistance; epithelial to mesenchymal phenotype; EMT;
differentiation; renal carcinoma; RCC.
1. Introduction
The formation of a malignant tumor is a complex and multi-stage process. This process is
dependent on tumor cells gaining various qualities that enable them to leave the original tumor and
subsequently inhabit the place where cancer metastasis has developed. The regulation of this process
takes place in many stages and depends among others on the presence and activity of the receptors
on the surface of cells. Receptors have particular importance in the process of growth, invasion and
metastasis possess tyrosine kinase activity [1]. One of the well-known receptors connected with
tumor growth and the metastatic process is the c-Met receptor, a product of the proto-oncogene MET.
The activation of the c-Met receptor through its ligand, hepatocyte growth factor (HGF), also known as
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the scatter factor (SF), leads to the stimulation of various biological effects. Under normal conditions,
this receptor takes part in embryogenesis, development of organs, differentiation of i.a. muscular
and nerve cells, as well as regeneration of the liver [2–4]. In tumor cells’ overexpression or incorrect
activation, this leads to the stimulation of proliferation, survival and an increase of motile activity.
This receptor is also described as a marker of cancer initiating cells. The latest research shows that the
c-Met receptor has its influence on the development of resistance to targeted cancer treatment [4,5].
In this review, we present recent advances that have been made in the study of the c-Met receptor
in kidney tumors, review the mechanisms underlying therapy resistance and summarize the evidence
on the role of the c-Met receptor in sustaining the undifferentiated mesenchymal phenotype of
cancer cells.
2. C-Met Receptor
C-Met is expressed by epithelial cells of many organs, including the liver, pancreas, prostate,
kidneys, lungs and bronchus. It is localized on the cells’ membrane and is activated upon binding
of Hepatocyte Growth Factor (HGF) or its splicing isoforms—the only known endogenous ligands
so far [6]. C-Met activation by HGF induces its tyrosine kinase catalytic activity which triggers
transphosphorylation of the tyrosine Tyr 1234 and Tyr 1235, initiating a whole spectrum of biological
activities including regulation of proliferation, cell motility or cell cycle progression [7].
Such a broad spectrum of HGF/c-Met actions led to the investigation of both MET gene expression
and c-Met activity in tumor cells. In fact, c-Met is deregulated in many types of human malignancies,
kidney, liver, stomach, breast and brain cancers. What is more, abnormal c-Met activation in cancer
specimens correlates with poor prognosis, where active receptor triggers tumor growth, angiogenesis
and metastasis. Today, MET is considered as a proto-oncogene and its mutations or overexpression
leads to aberrant, often constitutive activation of the HGF/c-Met axis [8,9]. Autocrine or paracrine
activation of c-Met is directly related to the promotion and progression of tumors in organs such as:
liver, lung, colon, breast, pancreas, ovary, prostate, stomach and kidney [6,10–12].
3. C-Met Receptor and Kidney Tumors
In the adult human kidney, the c-Met receptor is expressed in tubular epithelial cells where it
stimulates the growth of renal tubular cells [13–16]. Proper c-Met function is also important for the
induction of branching tubulogenesis during tubule repair following ischemic and chemical injuries or
contralateral nephrectomy [17–19].
Renal cell carcinomas (RCC) are divided into several major subtypes: the most common is
clear cell RCC (ccRCC, 75% of cases), papillary RCC (pRCC 15%) and chromophobe RCC (5%) [20].
Their common feature is a well-developed vascularization and, interestingly, upregulation of the c-Met
receptor level compared to the healthy kidney [21,22].
It has been shown that c-Met is overexpressed in renal cell carcinomas and its phosphorylation is
associated with progression of the disease [23,24].
ccRCC creates extremely vascularized tumors due to frequent loss of function mutation in the
von Hippel-Lindau tumor suppressor gene (VHL) located on chromosome 3p which is responsible for
regulating the stability of hypoxia-inducible factor 1 (HIF-1) [25]. The loss of VHL activity results in
HIFs accumulation which leads to excessive secretion of vascular endothelial growth factor (VEGF) or
platelet-derived growth factor (PDGF), as well as receptors that are potentially important in ccRCC
oncogenesis [26], resulting in increased ability of tumor cells to metastasis. It is also known that HGF
via its receptor c-Met may regulate VEGF expression and promote angiogenesis [27]. Furthermore,
it was shown that VHL mutation together with hypoxia lead to increased HGF and c-Met expression
in ccRCC [28,29]. In addition, HIF-1 during hypoxia regulates the expression of 1–5% of human genes,
inter alia c-Met and VEGF [30]. Thus, tumor angiogenesis together with c-Met receptor have become
a major focus of targeted therapy for RCC.
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In 1996, Natali and coworkers presented for the first time a comparison of c-Met expression
between the normal human kidney, urogenital tissue and 50 different histotypes of kidney tumors [23]
(Table 1). They showed a low level of c-Met receptor in tissues of the genitourinary tract in contrast to
a relatively high expression in tumor tissue. Such observations allowed scientists to link HGF/c-Met
axis with induction and progression of renal cancer cells [23]. Results published in the following year
by Pisters et al. also confirmed this observation. Out of 41 samples from normal and cancerous human
tissue analyzed by immunohistochemical (IHC) staining, 28 were positive for c-Met. Authors detected
c-Met in various subtypes of kidney tumors and correlated its amount with renal cell carcinoma (RCC)
stage assessed by the Fuhrman grading scale [31]. Nuclear grading of RCC, the so called Fuhrman
scale, was initially described in 1982 after prognostic evaluation of morphologic parameters in 103
patients diagnosed with renal cell carcinoma [32]. Four nuclear grades (1–4) were defined in order
of increasing nuclear size, irregularity and nucleolar prominence. Importantly, nuclear grade was
more effective than each of the other parameters (e.g. tumor size, cell arrangement or cell type) in
predicting the development of distant metastasis following nephrectomy. For example, among 45
tumors classified as nuclear grade 1, none of them metastasized for at least five years, whereas 50%
of the higher-grade tumors did [32]. As demonstrated by Pisters and coworkers, according to the
Fuhrman nuclear grade, c-Met was detected in 20 cases out of 24 (83%) in 3 and 4 grades, while only in
8 out of 17 (47%) cases of grades 1 and 2. Thus, the biological significance of the HGF/ c-Met pathway
in the development, progression and metastasis of kidney cancer was confirmed by the demonstration
of the correlation between c-Met expression and tumor progression [31]. Subsequent studies have also
described a high amount of c-Met receptor in renal tumors. In 2006, Choi and coworkers detected by
IHC staining exaggerated c-Met expression in 90% of papillary RCC, 100% of collecting duct carcinoma
and 92% of urothelial carcinoma [33]. MET expression was more heterogenous in clear cell RCC and
chromophobe RCC, where c-Met protein was detected by IHC staining in 45% and 8% of samples,
respectively. Next, Choi and coworkers correlated the expression of c-Met with the Fuhrman grade
in RCC specimens, together with clinical and pathological parameters related to the invasiveness or
aggressiveness of tumors. Importantly, they demonstrated that c-Met expression in clear cell RCC
correlated with high nuclear grade: stages I/II = 18%/29% versus stages III/IV = 58%/94% (p < 0.001).
Additionally, the level of c-Met protein correlated with tumor necrosis (p < 0.001) and the presence
of lymphatic invasion (p = 0.016) [33]. A recent study done by Gibney et al. also confirmed this
data. Among 303 RCC tumors paired with adjacent normal renal tissue, higher c-Met expression
was detected in all RCC subtypes than in the adjacent normal renal tissue (p < 0.0001). Additionally,
c-Met levels correlated with higher Fuhrman grades and more advanced disease stages [21]. However,
the differences were not significant; higher level of c-Met in grades III/IV = 39 versus grades I/II = 33
and III/IV = 38 versus stages I/II 34, which implicates that c-Met might be important in the early
stages of tumorigenesis.
3.1. C-Met is Associated with an Advanced Stage and Poor Survival of Patients
Although Fuhrman nuclear grading correlates with renal carcinoma severity, the patients’ survival
rate should be considered as the most important parameter. As such, the expression of c-Met should
also be correlated with survival analysis. Patients’ overall survival is affected by many factors, like:
the degree of local tumor advancement (T category), the presence of metastases in the lymph nodes
(N category) or the existence of distant metastases at the time of cancer diagnosis (M category) [34].
The staging system analyzing all the above mentioned criteria—a Classification of Malignant Tumors
(TNM) system —was developed by the American Joint Committee on Cancer (AJCC). The TNM
classification was developed as a tool for physicians to stage different types of tumors based on
certain standardized criteria and is now the most commonly applied staging system used by medical
professionals and scientists around the world. Analyses carried out by Pisters et al. in 1997 revealed
not only a correlation between c-Met expression and high nuclear grade (p = 0.008), however also
with TNM stage (p = 0.001) and disease-specific survival or metastases [31]. A later study of 303
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RCC samples demonstrated that higher c-Met expression correlated with worse disease-specific
survival (p = 0.0091) and was an independent predictor of survival [21]. More recently, analysis of
572 clear-cell RCC tumors demonstrated that only 17% were negative for c-Met expression, whereas
32% showed high protein levels. High c-Met was associated with an aggressive phenotype and
an unfavorable patient outcome [35] (Table 1). In accordance with these results, better overall survival
was demonstrated for patients characterized by RCC tumors with low c-Met expression in comparison
to high c-Met expressing subjects [36]. Interestingly, in 58% of cases (18 out of 31 cases), high c-Met
expression in primary tumors correlated with its amount in metastases. However, there was no such
relationship in 42% of specimens (13 out of 31) [37]. Conflicting results were also published by Miyata
and coworkers. In the latter analysis, total c-Met expression was not associated with a clinical and
pathological characteristic, however, c-Met was associated with an advanced stage and the presence of
metastases [24].
3.2. Germline and Somatic Mutations of C-Met Receptor in Renal Carcinomas
Most of the renal tumors revealed are sporadic. However, 4% of all detected kidney cancers can
be family-related among others in the group of von Hippel-Lindau or the Brit-Hogg-Dube band [28,38].
C-Met is a protein that in humans is encoded by the MET gene and is located in the 7q31 locus of
chromosome 7 [39]. Patients with tumors are identified by proto-oncogene mutations. Mutations that
cause constitutive phosphorylation of the c-Met receptor are identified in papillary kidney cancer at
13% (17/129) [40]. Hereditary papillary renal carcinoma (HPRC) is inherited and autosomal dominant
transmission occurs with reduced penetrance. In the case of malignant tumors, chromosomal trisomy
7, 16 and 17 occurs and, among men, the loss of the Y chromosome. Missense mutation is a point
mutation in which a single nucleotide change results in a codon that codes for a different amino acid
and, when located in the tyrosine kinase domain of the MET gene, it leads to constitutive activation of
the c-Met protein and papillary renal carcinomas [41]. Missense mutations involve replacing histidine
1112 with leucine (H1112L), histidine 1124 with aspartic acid (H1124D) or tyrosine 1248 with aspartic
acid (Y1248D). The mutations in the tyrosine kinase domain (amino acids 1110 to 1268) lead to the
inheritance of papillary renal carcinoma [40]. In the case of some patients with this type of tumor,
there is a chromosomal aberration involving chromosomal translocation which leads to fusion with the
MET gene and BAIAP2L1 or C8orf34. This results in protein coding with motifs that facilitate protein
dimerization, fusion and ultimately promote c-Met receptor kinase activity, even in the absence of
the HGF ligand [42]. The promotion of c-Met kinase activity in papillary renal carcinoma also occurs
during the V1110I mutation where the change of valine to leucine in the conserved ATP binding
pocket of the c-Met receptor enhances its kinase activity [43]. With the increase in c-Met protein
levels, there is also an increase in the number of MET copies in the primary and metastatic tumors.
According to Macher-Goeppinger et al., an increase in MET copy numbers was detected in 310 cases
out of 572. The number of copies per nucleus ranged from less than 2 (262/572 cases), from 2 to 4
(272/572) and the remaining 7% (38/572) more than 4 copies. MET copy number correlates with
dedifferentiation (p < 0.001), higher tumor extent (p < 0.001), positive lymph node status (p = 0.006)
and distant metastasis (p = 0.02). There was no consistent relationship between the number of MET
copies and the age of the patient [35] (Table 1).
Further studies showed that the increase in MET copy numbers correlates with poorer survival
and distant metastases in clear cell renal cell carcinoma [21].
3.3. Phosphorylation of C-Met in Renal Carcinomas
All the above mentioned results analyzed the amount of c-Met protein, which may not be
sufficient for a complete understanding of RCC biology. Today, we know that HGF binding by c-Met
leads to receptor homodimerization and autophosphorylation, which is a key event in its activation.
The study performed by Miyata et al. showed for the first time the expression of active c-Met receptor
- phosphorylated at Tyr 1349 residue. This active pY1349 c-Met receptor was mainly detected in
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cancer cell membranes and was positively associated with grade (p = 0.004), lymph node metastases
(p = 0.014), distant metastases (p = 0.021) and pT-stage (p < 0.001). Such tumors were also characterized
by higher proliferation rate (p < 0.001) and bigger tumor diameter (p = 0.017) in comparison to samples
without phosphorylated c-Met [24]. Additionally, positive expression of pY1349 c-Met was a significant
and an independent predictor of cause-specific survival (p = 0.028) [24] (Table 1).
Important data concerning c-Met activation in RCC comes from in vitro studies done by
Nakaigawa et al. [28]. They reported that c-Met in ccRCC cell line was constitutively activated
without HGF stimulation due to the inactivation of the VHL proto-oncogene. In this model, c-Met was
constitutively active even at an early stage of tumor formation, however constitutive phosphorylation
of the c-Met protein in vitro was inhibited by wild-type VHL gene delivery. Additionally, c-Met protein
activated by the inactivation of the VHL gene modified cell adherence, including N-cadherin
and beta-catenin. Scientists concluded that inactivation of the VHL gene induced constitutive
phosphorylation of the c-Met protein and modified intercellular adherence structure, triggering cell
growth released from contact inhibition, finally resulting in tumorigenesis [28].
The study performed by our group also showed that c-Met receptor phosphorylation is positively
associated with tumor growth and its vascularization, lung metastasis and ccRCC cells’ migratory
potential [44].
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Table 1. C-Met expression and phosphorylation in renal cell carcinomas (RCC) subtypes. The correlation between c-Met expression, protein level, receptor activation
and different stages of the tumor progression in patients with RCC.
Study (Year) Type c-Met DetectionMethod
Expression c-Met
(Number Positive/
Number Tested)
c-Met Expression
in Percent Major Conclusion
Natali et al.
(1996) [23] RCC
Immunohist-ochemical
(IHC) 39/45 87%
- increased expression at various levels in kidney cells of tumors with different
histological and cytological properties;
- c-Met may be involved in the formation and progression of renal cancer cells;
Pisters et al.
(1997) [31]
Papillary cell
IHC
3/3
68% - high expression of c-Met in renal cell carcinomas;
- correlation between the higher level of c-Met and higher nuclear grade
renal cancers;
Mixed clear and granular cell 24/37
Rhabdoid/sarcomatoid 1/1
Oncocytoma IHC 8/8 100%
Sweeney et al.
(2002) [45] Papillary renal carcinoma IHC 40/50 80%
20% of papillary cancers did not express c-Met—another possible mechanism
responsible for tumorigenesis;
- correlation of the growing stage of cancer with c-Met expression;
- a tendency for higher overall survival in patients with c-Met -negative tumors;
Jong Sun Choi et
al. (2006) [33]
Conventional renal carcinoma
IHC
43/96 45%
- significant relationship between c-Met expression and high nuclear level,
as well as several clinical–pathological parameters, which indicates tumor
invasion or aggressiveness;
- the ability to distinguish between RCC subtypes by diffuse and strong
immunoexpression of c-Met in RCC and collecting duct carcinomas as
compared to subtypes with tubulo-papillary growth;
Papillary renal carcinoma 18/20 90%
Chromophobe renal carcinoma 2/24 8%
Collecting duct carcinoma 5/5 100%
Urothelial carcinoma of renal pelvis 23/25 92%
Oncocytoma 0/12 0%
Miyata et al.
(2006) [24] RCC IHC 73/114 64%
- detection of pY1349 c-Met expression is an excellent predictor for the prognosis
of patients with sporadic conventional RCC because it is positively associated
with tumor grade, stage and size as well as cancer cell proliferation in patients;
Gontero et al.
(2008) [46] Papillary renal carcinoma IHC 13/46 29%
- positive c-Met expression was significantly more common in papillary RCC
(PRCC) type 2 (p < 0.001),
however lack of correlation with multifocal kidney disease (p = 0.86) and
occurrence of metachronous tumors (p = 0.93);
- c-Met expression had no prognostic value;
Mukai et al.
(2015) [47] RCC IHC 8/17 47%
- high c-Met and matriptase expression was found in RCC cells that had
metastasized to bone and was accompanied by matriptase expression in
osteoclasts, which indicates a significant role for these molecules in
bone metastasis;
Macher-Goeppinger
et al. (2017) [35] ccRCC
IHC and CISH
analyses 476/572 83%
- high expression of c-Met and MET copy number gains was associated with
clinical and pathological features in the primary tumor, an aggressive
phenotype and an unfavorable patient outcome;
- c-Met expression and MET copy number should be used in relapses or
metastases to target anti c-Met therapy in patients with ccRCC;
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4. Resistance to Anti-Cancer Therapies in RCC
The c-Met receptor has become a therapeutic target in many cancers as well as in kidney cancer.
Selective inhibitors of c-Met are currently in the clinical development phase. Inhibiting abnormal c-Met
activity can significantly increase patient survival, reduce the rate and extent of metastasis and prolong
the lives of patients who are often diagnosed only at advanced stages of cancer. Unfortunately,
regardless of this, the therapies used so far using c-Met tyrosine kinase inhibitors demonstrate
resistance to treatment [48].
Resistance to anti-cancer therapies is a known phenomenon that is still not fully understood.
Many tumors, despite the first good response, over time develop strong resistance to the drugs
used [49–51]. Mechanisms underlying resistance are based, among other things, on drug inactivation,
alternative signaling pathways activation, drug target alteration and the epithelial-mesenchymal
transition [52,53].
RCCs are usually not sensitive to chemotherapy and the majority of drugs used in RCC
target angiogenic pathways. Up to now, several drugs have been created that target the VEGF
and PDGF pathways. Bevacizumab and nivolumab are monoclonal antibodies targeted at VEGF
and PD-1. Everolimus and temsirolimus, second line mTOR inhibitors, downregulate both cell
proliferation and angiogenesis. Whereas, drugs such as sunitinib, sorafenib, pazopanib, axitinib,
lenvatinib and cabozantinib are the largest family of tyrosine kinase inhibitors (TKIs) [54–60]. TKIs act
as anti-angiogenic agents through the inhibition of tumor endothelium growth and cell survival
signaling impairment [56,57]. As multi-targeted agents, they inhibit number of receptors with varying
potency such as VEGFRs, PDGFR and, recently, also c-Met, which are involved in several signaling
pathways [61].
Despite the overall longer survival rate and first good response, eventually all patients with
metastatic RCC show resistance to the anti-angiogenic therapy, especially to TKIs. Suppressing the
VEGF pathway initially decreases tumor progression and vascularization, however after a couple of
months of treatment, rapid recurrence occurs [49,62]. Prolonged exposure of tumor cells to sunitinib
results in quick drug resistance development. Interestingly, in vitro studies have shown that such
resistance may be transient and cells sensitivity is restored after some period of drug-free culture,
both in selected RCC patients and tumor models, suggesting epigenetic tumor adaptation to TKIs [63].
The main mechanisms underlying the emergence of acquired resistance to the used
anti-angiogenic therapies is the epithelial to mesenchymal transition [53] and the compensation
of blocked receptors as well as the activation of alternative proteins or signaling pathways such
as the HGF/c-Met pathway, which could drive tumor angiogenesis or growth independently from
VEGFRs [64–66]. Also, lack of influx of endothelial cells caused by lack or blockade of VEGF may
cause vasculogenic mimicry within tumors that takes the role of endothelium and forms structures
similar to blood vessels [67,68] (Figure 1).
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(non-tumor compartment) contribute to the development of resistance to sunitinib therapy due to 
upregulated HGF expression in stroma cells of mesenchymal origin. The main target for secreted 
HGF were c-Met on the surface of endothelial cells within the tumor, which indicates that the tumor 
vasculature mainly responds with the resistance to the sunitinib therapy by a shift to the alternative 
signaling pathway [64]. It is worth noting that studies on IL8 role in resistance to sunitinib have 
shown that endothelial cells are sensitive to sunitinib whereas tumor cells are only minimally [69]. 
Interestingly, after the combination of sunitinib and a highly selective c-Met inhibitor, PF-04217903 
growth inhibition was observed, however, only in sunitinib resistant tumors [64]. Similar results were 
observed in a pancreatic tumor study [65]. It was found that after sunitinib treatment of transgenic 
RIP-Tag2 mice, tumor growth slowed and reduced vascularity, however there was an increased 
hypoxia together with HIF1α accumulation, upregulation of c-Met receptor and epithelial to 
mesenchymal transition (EMT) markers such as Snail1, N-cadherin and vimentin. However, after the 
introduction of c-Met inhibitor PF-04217903 to crizotinib or sunitinib treatment, invasion and liver 
metastasis as well as c-Met and EMT markers expression were reduced [65]. The inhibition of both 
signaling pathways by cabozantinib (XL184), a dual c-Met and VEGFRs inhibitor, also reduced tumor 
growth, invasion, metastasis and prolonged survival of RIP-Tag2 mice [65]. Studies conducted using 
a 786-O cell line characterized by a high level of c-Met showed that the combination of anti-
angiogenic agent axitinib (which targets all VEGFRs) with crizotinib inhibits tumor growth and 
reduces vascularization compared to individual therapy with these drugs. The same effect was 
Figure 1. C-Met receptor and resistance to anti-cancer therapies in RCC. RCC tissue is characterized
by a high level of c-Met receptor. Under treatment with VEGFRs inhibitors such as sunitinib,
sorafenib, pazopanib, axitinib or lenvatinib, c-Met is phosphorylated and activates many downstream
pathways involved in survival, proliferation, motility, invasiveness and angiogenesis which leads to
the development of resistance. Dual blockade of the c-Met receptor and VEGFRs causes induction of
apoptosis and inhibition of tumor growth.
4.1. C-Me Receptor and Therapy Resistance
Shojaei et al. were first to show that the HGF/c-Met pathway acts as an alternative pathway in
sunitinib resistant tumors [64]. They demonstrated that not only tumor cells, however also stroma
(non-tumor compartment) contribute to t development of resistance to sunitinib th rapy due to
upregulated HGF expression in stroma cells of mesenchymal origin. Th main targ t for sec eted
HGF were c-Met on th surface of endothelial cells withi the tumor, which indicates that the t mor
vasculature mainly responds with the resistance to the sunitinib therapy by a shift to the alternative
signaling pathway [64]. It is w rth n ting that studies on IL8 role in resistance to sunitinib have
shown that endothelial cells are sensitive to sunitinib whereas tumor cells re only minimally [69].
Interestingly, after the combination of sunitinib and a highly selective c-Met i hibitor, PF-04217903
gr th inhibition was observed, however, only in sunitinib r sistant tumor [64]. Similar results were
observed in a pancreatic tumor study [65]. It was found t at after sunitinib treatment of transgenic
RIP-Tag2 mice, tumor growth slowed and reduced vascularity, however there was an increased hypoxia
tog th r with HIF1α ac umulation, upregulation of c-Met receptor and epith lial to mesenchymal
transition (EMT) markers suc as Snail1, N-cadherin and vimentin. How ver, after the i troduction
of c-Met inhibitor PF-04217903 to crizotinib or sunitinib treatment, invasion and liver metastasis
as well as c-Met and EMT markers expression were reduced [65]. The inhibition of both signaling
pathways by cabozanti ib (XL184), a dual c-Met and VEGFRs i hibitor, also reduced tumor growth,
invasion, metastasis and prolonged survival of RIP-Tag2 mice [65]. Stu ies conducted using a 786-O
cell line characterized by a high level of c-Met showed that the combination of anti-angiogenic agent
axitinib (which targets all VEGFRs) with crizotinib inhibits tumor growth and re uces vascularization
compared to individual therapy with these drugs. The same eff ct w s observed i the suniti ib
resistant RP-R-01 ccRCC PDX model, however not in the sunitinib sensitive one (with l c-Met
levels) [70]. Similar results, showe by Zhou et al., indic te that resistance to sunitinib was induced by
Cells 2019, 8, 272 9 of 17
upregulation of c-Met and AXL receptors which promotes pro-metastatic behavior and angiogenesis
in ccRCC [66]. Furthermore, chronic exposure to sunitinib promotes EMT signaling, upregulates
levels of c-Met downstream proteins such as ERK, Akt and Src and elevates cell migration and
invasion in vitro and in vivo [66]. EMT signaling was impaired after AXL or c-Met suppression with
specific shRNA, which indicates that chronic sunitinib treatment is AXL and c-Met dependent. Also,
tumor angiogenesis (tube formation) was reduced after AXL or c-Met inhibition in RCC cell line
786-O co-cultured with endothelial cells HUVEC [66]. Moreover, administration of cabozantinib
results in suppressed EMT phenotype and VEGF secretion and rescues sunitinib resistance. Treatment
with cabozantinib reduced tumor size during in vivo experiments [66]. Interestingly, it was shown
that HIF1α directly activates the expression of AXL by binding the hypoxia-response element to the
AXL promoter. AXL together with its ligand growth arrest-specific 6 (GAS6) form a complex with
SRC proto-oncogene and activate c-Met in an HGF-independent manner which leads to increased
migration and invasion of ccRCC [71]. After using two inhibitors specific for AXL (sAXL) and c-Met
(ARQ197), it was shown that sAXL therapy reduced invasion by 70% while c-Met inhibition only
by 40%. This suggests that GAS6/AXL signaling activates c-Met to maximize invasion through
noncanonical signaling mechanisms in RCC [71]. Recently, c-Met was proposed as a prognostic marker
in patients with metastatic RCC (mRCC) treated with sunitinib due to the correlation of higher c-Met
expression with faster resistance to sunitinib [72].
The undeniable benefits of combining anti-angiogenic therapies with blocking the c-Met receptor
have prompted scientists to create one drug that is a combination of VEGFR and c-Met inhibitors.
Cabozantinib is a novel TKI that targets VEGFR-2, c-Met, AXL, RET, KIT, Tie-2 and FLT3, which are
involved in invasiveness, metastasis and survival [73]. It was approved in 2016 by the US Food
and Drug Administration (FDA) for treatment of patients with mRCC following anti-angiogenic
therapy [74]. In phase I of the clinical trial on 25 patients pretreated with VEGF or mTOR inhibitors,
after cabozantinib administration (maximum 140 mg daily), a 28% response rate with a median
progression-free survival (PFS) of 12.9 months was observed [75]. The phase II randomized trial in
metastatic RCC cabozantinib (79 patients) versus sunitinib (78 patients) revealed significantly longer
median cabozantinib PFS of 8.6 months compared with 5.3 months with sunitinib and overall survival
(OS) was 26.6 versus 21.2 months for cabozantinib [76]. Finally, a phase III randomized trial METEOR
investigated cabozantinib versus everolimus in 658 patients with PFS 7.4 versus 3.9 and OS 21.4 versus
16.5 for cabozantinib [77]. Cabozantinib seems to be a very good second-line therapy for patients
with mRCC, having very good results of PSF or OS in comparison with other therapeutics used in the
treatment of RCC due to wide spectrum of targeted kinases, especially c-Met and AXL.
Lastly, foretinib, a multikinase inhibitor targeting c-Met, VEGF, AXL, RON and Tie-2, was tested on
patients with papillary renal cell carcinoma. pRCC is often characterized by mutations or amplification
in the MET gene. In the phase II randomized clinical trial on foretinib, patients were classified based
on c-Met pathway activation: germline or somatic mutation, MET [7q31] amplification or gain of
chromosome 7. Foretinib demonstrated activity in patients with pRCC with median PFS 9.3 and a high
response rate in patients with germline MET mutations [78]. Despite a relatively good response to the
drug and several clinical trials, work on foritinib has been discontinued.
Anti-angiogenic therapies of RCC, based on TKIs, such as sunitinib or axitinib show significant
benefits in vasculature reduction and decrease of tumor size, especially in ccRCC patients. However,
despite the initial good response, relapse occurs due to the acquisition of resistance, resulting in
a shift to alternative pathways that will support and promote angiogenesis. The c-Met/HGF signaling
pathway plays a significant role in tumor and endothelial cells where it acts as a potent pro-angiogenic
trigger. New TKIs, which target not only VEGFR, however also the c-Met receptor, appear to be
a response to the problem of resistance, showing a similar tolerance and toxicity as first-line TKIs,
yet a superior PFS response and efficiency (Figure 1).
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4.2. Epithelial to Mesenchymal Transition in the Acquisition of Therapeutic Resistance
Developing resistance to treatment that limits the success of cancer therapy is one of the
most difficult problems of the contemporary oncology. Despite significant progress in the use
of chemotherapy over the past 40 years, most chemotherapeutic regimens have failed to provide
satisfactory therapeutic outcomes due to relapse caused by resistance to treatment. Understanding the
molecular mechanisms that cause resistance to a therapy is of great importance for the development of
alternative therapies and the improvement of clinical benefits. Most of the mechanisms of resistance
include, among others, secondary mutations of inhibited pathways or amplifications of growth factor
receptors. However, it seems that the resistance acquisition process is more complex and dependent
on a number of changes in the tumor cell itself and in the tumor microenvironment.
The acquisition of therapeutic resistance and progression to distant metastatic disease might be
a result of the epithelial to mesenchymal transition (EMT) process.
The epithelial to mesenchymal transition was observed for the first time in the context of
embryonic development, where it regulates key morphogenetic steps such as gastrulation and neural
crest formation [79]. EMT is also a key element of tumor progression in which epithelial cells acquire
mesenchymal features facilitating their migration, invasion of neighboring tissues and metastasis.
During EMT, clearly polarized epithelial cells with high expression of E-cadherin and other proteins
characteristic for epithelial cells phenotype, under the influence of growth factors, cytokines and
other environmental factors change their morphology to an elongated one and become migrating
cells with the expression of i.e. vimentin, fibronectin, N-cadherin and a decrease of E-cadherin [80].
E-cadherin is a transmembrane protein located in the adherens junctions, playing an important role in
the sustaining of the epithelial morphology and the inhibition of the invasion and metastasis of the
cancer cells. Loss of the expression of E-cadherin is a well-known sign of the EMT, which may cause
the transformation of the non-malignant tumor into a locally aggressive and invasive form [81]. It has
also been demonstrated that the induction of EMT in epithelial tumor cells results in the acquisition
of features of tumor-initiating cells, also designated as cancer stem cells (CSCs) [82,83]. Cancer cells
with stem cell characteristics have been found to be enriched in the residual tumors remaining after
standard chemotherapeutic treatments [84].
5. C-Met Receptor as a Marker of Undifferentiated Cells
The c-Met receptor has been postulated as an essential factor responsible for the functional cancer
stem cell (CSC) phenotype in some tumors and as a CSC factor, it is believed to be responsible for
therapy resistance [85].
The results obtained by our team and other research groups have shown that the c-Met receptor
is also important in the process of cell differentiation and resistance to chemotherapy for some tumors.
In the biology of rhabdomyosarcoma, one of the most common tumors found in the soft tissues of
children, the c-Met receptor is very important for the process of proliferation, survival and resistance
to chemotherapy [86–89]. RMS cells lacking the c-Met receptor were more differentiated and had
a significantly reduced level of MyoD transcription factor, the marker for undifferentiated cells [86].
It has also been shown that in the RMS cells subjected to a differentiation process, they displayed
a significant decrease of MyoD and myogenin factors that are characteristic of the rhabdomyosarcoma.
The process of differentiation decreases the c-Met receptor level significantly. What is more, these cells
changed their morphology to a more elongated one and lost their ability for active migration.
The obtained results clearly indicated the significant role that the c-Met plays in the sustaining of the
RMS phenotype. The research has proven that the c-Met receptor is a significant factor for sustaining
the rhabdomyosarcoma cells in an undifferentiated state. RMS may derive from a differentiation
defect of either mesenchymal stem cells (MSC) or myogenic progenitors [90]. It has been shown that
activation of c-Met signaling blocks myogenic differentiation of RMS and may be responsible for
the impairment of myogenic differentiation of MSC and, as a consequence, may lead to oncogenic
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transformation towards embryonal RMS development [88]. It has been shown that in muscle satellite
cells, c-Met activation inhibits the exit from the cell cycle and delays myogenic differentiation [91].
The silencing of the c-Met receptor results in changes of the phenotype in other types of tumor
cells. Similar research has shown that the silencing of the c-Met receptor in cervical cancer cells
with epithelial origin induced the increase in the level of E-cadherin [92]. Decreased c-Met level also
increases the level of E-cadherin in tumors of NOD-SCID mice. The cells with silenced expression
of the c-Met receptor have a decreased level of Slug transcription factor, one of the repressors of
E-cadherin expression [92,93].
Interesting results also came from research on lung cancer where the reinstitution of the E-cadherin
expression increased the cancer cells’ sensitivity to the cytostatic drug, gefitinib [94]. Summarizing the
above, our research has shown that the c-Met receptor is responsible for sustaining the mesenchymal
phenotype in cervical carcinoma cells (Figure 2).
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Figure 2. C-Met receptor as a marker of undifferentiated cells. Cancer cells with epithelial phenotype
under hepatocyte growth factor (HGF) stimulation, epithelial to mesenchymal transition (EMT) or MET
gene mutations acquire characteristics of undifferentiated, mesenchymal cells. Activation of c-Met
leads to downregulation of E-cadherin and upregulation of N-cadherin and vimentin which cause
increased survival, motility and invasiveness of cancer cells.
However, the role of the c-Met receptor in the acquisition of mesenchymal phenotype is not
well understood for kidney cancer. Our group has already shown that in an in vitro model of clear
cell renal cell carcinoma cells and in the normal human renal cell line HEK293, increased level
and phosphorylation of c-Met correlates with the acquisition of mesenchymal cell characteristics,
i.e. an increase in the migration activity, the suppression of E-cadherin and upregulated β-catenin and
vimentin [44]. The increased c-Met activation was the result of the lack of anti-inflammatory MCPIP1
protein that controls the inflammatory process. Our observation showed that low level of MCPIP1 in
ccRCC led to an increased tumor growth, vascularization and lung metastasis in both NOD-SCID and
Nude mice together with the loss of epithelial phenotype of cancer cells [44].
The presence of the c-Met receptor is crucial not only for the high level of proliferation and
initialization of tumor growth in in vivo conditions, however is also a significant factor in sustaining
the undifferentiated/mesenchymal phenotype of cancer cells (Figure 2).
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6. Conclusions
The c-Met receptor plays a significant role in healthy kidney and RCC development. Paracrine or
autocrine HGF stimulation, EMT or MET gene mutations lead to c-Met activation and stimulation of
various pathological effects, such as proliferation, survival, angiogenesis and increased motile activity.
In addition, this receptor is described as a marker of cancer initiating cells. All this leads to tumor
growth and progression.
Here we showed that c-Met level is upregulated in RCC tumor tissue compared to normal
kidney and increases during RCC progression. Frequent VHL mutation and hypoxia lead to increased
c-Met expression in clear cell RCC. In papillary RCC, missense mutation of the MET gene causes
constitutive activation of the c-Met protein, which correlates with poor survival rates. The c-Met
receptor becomes one of the main factors involved in acquiring resistance to targeted therapies
used in RCC. Mechanisms underlying therapy resistance consist of the compensation of blocking
VEGFRs by activating other receptors involved in the regulation of angiogenesis such as the c-Met.
Therefore, combination treatment of anti-angiogenic drugs with c-Met inhibitor reduces tumor growth,
vascularization and VEGF secretion. Moreover, the role of the c-Met in tumor progression is extremely
significant through its impact on sustaining the undifferentiated mesenchymal phenotype of cancer
cells, which consequently is responsible for therapy resistance.
Taken together, c-Met is an important factor involved in the acquisition of resistance to targeted
therapies, sustaining mesenchymal, undifferentiated phenotype, and increased renal carcinomas’
growth, progression and invasiveness.
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